IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.440
EU - Europa 3.345
NA - Nord America 3.343
SA - Sud America 894
AF - Africa 58
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.099
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.213
RU - Federazione Russa 1.940
SG - Singapore 1.223
CN - Cina 1.062
BR - Brasile 736
HK - Hong Kong 544
SE - Svezia 338
IT - Italia 323
VN - Vietnam 272
DE - Germania 169
FR - Francia 168
GB - Regno Unito 92
AR - Argentina 71
BD - Bangladesh 67
FI - Finlandia 65
IN - India 58
CA - Canada 57
MX - Messico 45
AT - Austria 38
IQ - Iraq 33
EC - Ecuador 32
PL - Polonia 32
JP - Giappone 29
NL - Olanda 29
ID - Indonesia 28
ES - Italia 26
IE - Irlanda 23
GR - Grecia 21
CO - Colombia 19
AU - Australia 18
ZA - Sudafrica 18
BE - Belgio 17
UA - Ucraina 16
PK - Pakistan 15
TR - Turchia 15
AE - Emirati Arabi Uniti 14
VE - Venezuela 14
PY - Paraguay 12
SA - Arabia Saudita 11
IL - Israele 9
TN - Tunisia 9
MD - Moldavia 8
MY - Malesia 8
LT - Lituania 7
MA - Marocco 7
UZ - Uzbekistan 7
KE - Kenya 6
NO - Norvegia 6
ET - Etiopia 5
JM - Giamaica 5
JO - Giordania 5
NP - Nepal 5
BB - Barbados 4
BH - Bahrain 4
KZ - Kazakistan 4
LU - Lussemburgo 4
PA - Panama 4
PH - Filippine 4
SN - Senegal 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CL - Cile 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EG - Egitto 3
GT - Guatemala 3
HN - Honduras 3
KR - Corea 3
LB - Libano 3
LV - Lettonia 3
PE - Perù 3
UY - Uruguay 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GE - Georgia 2
IR - Iran 2
RS - Serbia 2
TW - Taiwan 2
AI - Anguilla 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
DZ - Algeria 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LS - Lesotho 1
LY - Libia 1
ML - Mali 1
NA - Namibia 1
OM - Oman 1
PT - Portogallo 1
QA - Qatar 1
SC - Seychelles 1
Totale 11.094
Salva come PNG Salva come JPEG
Città #
Dallas 1.390
Singapore 636
Hong Kong 541
Moscow 447
Ashburn 365
San Jose 290
Shanghai 225
Hefei 149
Beijing 147
Lauterbourg 127
New York 126
Lawrence 97
Princeton 97
Ho Chi Minh City 93
Milan 84
Los Angeles 59
Hanoi 57
Nuremberg 56
São Paulo 54
Munich 44
Boardman 40
Rome 35
Warsaw 29
Helsinki 24
Dublin 23
Tokyo 23
Buffalo 22
Chennai 22
Orem 20
Rio de Janeiro 20
Turku 20
Da Nang 19
Denver 19
Guangzhou 19
Montreal 19
Santa Clara 19
Vienna 19
Council Bluffs 18
Houston 18
Poplar 17
Thessaloniki 17
Boston 16
Brooklyn 16
Hangzhou 16
Phoenix 15
Brasília 14
Frankfurt am Main 14
Lappeenranta 14
Chicago 13
Manchester 13
Mexico City 13
Atlanta 12
Johannesburg 12
Porto Alegre 12
Stockholm 12
Baghdad 11
Belo Horizonte 11
London 11
Brussels 10
Columbus 10
Curitiba 10
Monza 10
Naples 10
Querétaro 10
Shenzhen 10
Toronto 10
Amsterdam 9
Guarulhos 9
Quito 9
Ribeirão Preto 9
Asunción 8
Biên Hòa 8
Dubai 8
Haiphong 8
Oviedo 8
The Dalles 8
Wuxi 8
Bari 7
Florianópolis 7
Guayaquil 7
Jakarta 7
Mumbai 7
Ninh Bình 7
San Francisco 7
Zhengzhou 7
Buenos Aires 6
Cleveland 6
Dhaka 6
Goiânia 6
Istanbul 6
Jiaxing 6
Manaus 6
Medellín 6
Mol 6
Nairobi 6
Osasco 6
Seattle 6
Sydney 6
Tashkent 6
Turin 6
Totale 6.089
Salva come PNG Salva come JPEG
Nome #
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 451
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 427
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 413
Exploring Perceptions, Opinions, and Needs of Adult and Pediatric Cancer Patients, Caregivers, and Healthcare Professionals Towards Low-Fidelity Versions of the MyPal Project's Applications: Findings from 12 Pre-Pilot Focus Groups in 4 European Countries of an ePRO Intervention for Palliative Cancer Care (Preprint) 194
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 144
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 142
Chronic lymphocytic leukaemia 131
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 124
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 116
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 113
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 112
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 107
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 106
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 106
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 99
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 99
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 98
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 94
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 94
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 93
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 92
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 91
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 91
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 91
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 91
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 90
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 90
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 89
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 88
Targeting B-cell anergy in chronic lymphocytic leukemia. 88
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 87
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 87
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 86
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 86
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 83
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 83
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 82
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 82
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 82
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 82
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 80
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 80
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 78
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 77
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 77
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 75
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 75
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 75
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 73
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 73
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 73
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 72
Loss of CYLD promotes splenic marginal zone lymphoma 72
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 72
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 72
Monoclonal B lymphocytosis in the general population 71
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 70
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 69
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 68
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 68
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 68
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 67
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 67
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 67
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 67
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 67
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 67
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 66
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 66
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 66
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study 65
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 65
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 65
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 64
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 64
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 63
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 63
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 63
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 62
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 61
Co-Designing Smartphone Notifications According to the Clinical Routine of Cancer Patients 61
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 61
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 61
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 60
Relevance of Minimal Residual Disease in the Era of Targeted Agents 60
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 58
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 58
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 57
Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations 57
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 57
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 56
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 56
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 56
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 56
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 56
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 55
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 55
Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies 54
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study 54
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency 53
Totale 8.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.352
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202275 0 0 0 21 6 3 8 19 7 6 2 3
2022/2023616 215 113 54 1 16 82 23 34 40 8 11 19
2023/2024477 13 20 27 119 22 71 4 27 1 12 44 117
2024/20252.285 276 53 63 60 87 164 243 215 393 340 182 209
2025/20267.831 544 1.018 1.057 992 542 191 555 487 1.798 375 221 51
Totale 11.378